The trial included 926 individuals, 70 % of whom had their disease progress throughout a six-calendar year period. This median 10-month benefit in delaying disease progression shows that statins could be a valuable addition to your current therapies for prostate tumor, says the study's first author, Lauren Harshman, MD, medical oncologist in the Lank Middle for Genitourinary Oncology in Dana-Farber. These results are supported by multiple prior epidemiologic research demonstrating that statin make use of may be connected with improved outcomes in prostate tumor, but need validation. Related StoriesViralytics enters into medical trial collaboration contract with MSDCrucial switch in single DNA bottom predisposes children to intense type of cancerCornell biomedical engineers develop 'super natural killer cells' to destroy cancer cells in lymph nodesThe trial grew out of laboratory studies that recommended statins could delay prostate malignancy growth in individuals receiving ADT. Continue reading

Complementary to the exiting US FDA – 21 CFR Component 11 compliant laboratory procedure, and multiple ISO certifications, the CAP qualification enables BGI to supply the highest international regular of excellence in quality laboratory procedures. Furthermore, the BGI Total Quality Plan, with a 24/7, real-time customer care program, provides industry-leading consumer services to your clients. Built with the industry's broadest selection of genomics technologies, plus a skilled group of scientists and bioinformaticians, BGI supplies the highest-quality data and solutions for researchers and clinicians from worldwide.. BGI’s DNA sequencing laboratory in Hong Kong accredited by CAP BGI announced today that its high-throughput DNA sequencing laboratory in Hong Kong has been accredited by the American University of Pathologists . Continue reading

CardioNova initiates Phase 1b clinical trial with AtheroNova’s AHRO-001 AtheroNova Inc www.sildenafil-au.com . , a biotech company focused on the research and development of substances to safely regress atherosclerotic plaque and improve lipid profiles in humans, announces that its partner today, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001. This Phase 1b trial is a continuation of the AHRO-001 Phase 1 security trial finished in February 2014, in which patients had been dosed with AHRO-001 for three weeks. The Company will remain blinded to data from the earlier Phase 1 cohorts until the completion of Phase 1b, at which time the topline data will end up being presented collectively in approximately 6 to 8 months. Continue reading

Page 4 of 41234